India Pharma Outlook Team | Monday, 02 February 2026
Eli Lilly has agreed to a major collaboration with biotech firm Repertoire Immune Medicines in a deal valued at up to $1.93 billion to develop new autoimmune therapies that aim to change how these diseases are treated.
The deal provides Repertoire with an initial payment of $85 million and up to 1.84 billion as the businesses meet development and commercial targets, as well as, tiered royalty rates on subsequent sales.
Combining the efforts of the two companies will aid in the designing of treatments that extend past the unselective immune suppression to aid the restoration of an immune equilibrium in a patient. Lilly obtains Repertoire DECODE platform which is a technology that maps the mode of T cell recognition of diseased cells which is a pivotal move towards designing more specific therapies.
Also Read: Navigating the New Era of Nitrosamine Compliance
By using this platform, Repertoire will be concentrated on the discovery at the early stage, and Lilly will continue with clinical trial, regulatory measures, production, and marketing in case the candidates succeed.
Repertoire’s CEO, Torben Straight Nissen, said the collaboration expands the company’s pipeline of “tolerising therapies” and brings the chance to turn its discoveries into medicines that could offer lasting remissions for people with autoimmune conditions. He emphasized that Lilly’s strength in immunology and commitment to unmet patient needs makes the partnership especially promising.
The deal of autoimmune therapies is one of the many attempts by Lilly to expand beyond the well-established diabetes and obesity drugs. It is also making huge investments in immunology with recent acquires and other collaborations. The most recent partnership will place Lilly in a better position to bring innovative immune-modulating therapies to patients struggling with ailments like rheumatoid arthritis, lupus and others that require better-suited treatments.
.jpg)
